Which TKI combinations have been investigated for the treatment of HER2-positive breast cancer?

Updated: May 14, 2019
  • Author: Maurie Markman, MD, MS; Chief Editor: Karl S Roth, MD  more...
  • Print


Several ongoing phase I/II trials are investigating this TKI combination with trastuzumab, paclitaxel, or vinorelbine in patients with trastuzumab-refractory breast cancer. Other EGFR TKIs, such as gefitinib and erlotinib, have been studied in combination with trastuzumab and endocrine therapy with disappointing results.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!